NCT03345342 – A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation Posted on August 5, 2023 by tsuperadmin -
NCT01559272 – A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia Posted on August 5, 2023 by tsuperadmin -
NCT00668837 – Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia Posted on August 5, 2023 by tsuperadmin -
NCT02713282 – A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation Posted on December 12, 2019 by tsuperadmin -
NCT01515423 – A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia Posted on December 12, 2019 by tsuperadmin -
NCT00566631 – Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia Posted on December 12, 2019 by tsuperadmin -
NCT00460512 – An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia Posted on December 12, 2019 by tsuperadmin -
NCT00034775 – Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres Posted on October 25, 2019 by tsuperadmin -
Open-label Study Exploring a Switching Regimen From Depot Neuroleptics to Risperidone Depot Microspheres Posted on August 23, 2019 by tsuperadmin -
NCT00526877 – Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres Posted on March 18, 2019 by tsuperadmin -
The YODA Project